Relugolix (Ryeqo) with low‑dose add-back hormones for uterine fibroids and endometriosis and its effects on blood clotting

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an interventional, single‑center study at Hôpitaux Universitaires de Genève that gives prescribed Ryeqo to eligible adult women and measures hemostasis parameters over treatment. Ryeqo combines relugolix with low‑dose estradiol and progesterone to suppress ovulation while limiting hypoestrogenic symptoms. Patients must be ≥18, French‑speaking, and not have used certain hormonal therapies in the prior three months. Blood markers of coagulation and related hemostasis measures are collected to detect potential changes associated with the medication.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition
* Age ≥ 18 years

Exclusion Criteria:

* Unable to speak and/or read French
* Having used either an oestro-progestin pill (oral, patch or vaginal ring) or oral estrogens in the past 3 months, or DMPA or nomegestrol acetate
* Women not having given their consent to participate in the study

Where it's running

• Hôpitaux Universitaires de Genève
  Geneva, Canton of Geneva, Switzerland Recruiting

Study contacts

• Study coordinator: Manuela Viviano, MD
• Email: manuela.viviano@hug.ch
• Phone: +41 79 55 35 385

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating uterine fibroids using ultrasound techniques before and after treatment

  This study is testing if a special ultrasound can help women with uterine fibroids see how their condition changes before and after a specific treatment called uterine artery embolization.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT06705075

• Using Bearing nsPVA particles for treating uterine fibroids

  This study is testing if a new type of particles used in a procedure can safely help women with painful uterine fibroids feel better.

  Recruiting at 3 sites Merit Medical Systems, Inc. · Brooklyn, New York and 3 other locations · NCT06153667

• Impact of Uterine Fibroids on Women's Fertility

  This study looks at how uterine fibroids might affect pregnancy rates in women aged 20-50 who are struggling with infertility.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06020924

• Uterine Fibroids in China: How Common They Are and What Increases Risk

  This study tests how common uterine fibroids are in Chinese women and what factors relate to developing them and needing surgery.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT05840042

• Registry for pregnancy outcomes after Exablate treatment for uterine fibroids

  This study is looking to see how the Exablate treatment for uterine fibroids affects pregnancy outcomes in people who have had the procedure.

  Recruiting at 5 sites InSightec · Los Angeles, California and 5 other locations · NCT05386615

• Vitamin D3 for symptomatic uterine fibroids in women with vitamin D deficiency

  This trial will try giving vitamin D3 for six months to women with symptomatic uterine fibroids and low vitamin D to see if their symptoms and fibroid size improve.

  Recruiting at 2 sites Early Phase 1 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Dhaka, Sahabag and 1 other locations · NCT07012161

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.